Upozornění: tyto stránky používají cookies. Používáním těchto stránek s tím souhlasíte.

One of Nanopharma's main competitive advantages is its strong orientation on research and development of promising new uses for nanofiber structures and the company's ability to respond quickly to developments in this area.

The R&D team works closely with the sales and business development departments to make sure that new initiatives are supported with plenty of comprehensive market data. This organizational cooperation makes it possible to quickly connect our tech experts with their counterparts at our R&D partners and flexibly develop interesting collaborative projects.

Nanopharma is currently working with a number of prestigious universities, research institutions, and biotechnical and manufacturing companies around the world, and is also actively seeking out new partners.


 R&D1  R&D2  R&D3
Direct participation or subcontracting programs TAČR, GAČR and OPPIK. Partners or subcontractors to H2020 and Eurostars programs. Based on mutual agreement with partner(s).


Nanoprogres Nanopharma has been active in the Czech nanotechnology cluster called Nanoprogres since 2010 as a founding member, mainly participating in its collective projects of applied research in the area of nanofiber materials. The high level of specialization, access to the latest research infrastructure and concentration of knowledge and resources needed have allowed the cluster to develop new, highly innovative solutions for preparation and application of coaxial nanofiber structures.     AREAS OF COOPERATION incorporating active ingredients developing new functionalized membranes preparing cell carriers for tissue engineering developing functional layers for composite materials preparing nanofiber structures upon request

CURRENT PROJECTS: International technological cooperation program

Nanopharma is working with an Australian partner under a Czech Ministry of Industry and Trade program to develop functionalized biocompatible carriers for controlled delivery of active ingredients in the area of medicine and industry.


ThymiStem Project carried out by Nanopharma and an international team of scientists under the FP7 program (602587). The goal is to develop processes to regenerate human thymus, thus strengthening the immune system in immunocompromised patients. Nanopharma's role consists of developing sophisticated 3D scaffolds to create a functional thymus organoid.

If you are interested in working with Nanopharma, please contact us through the contact form in the Contact section, or write directly to Liliana Berezkinová, Sales and Business Development Director: .